ABC.L Regulatory News (ABC)

22 Dec 2006 07:00

ABCAM Plc22 December 2006 For immediate release 22 December 2006 ABCAM PLC ("Abcam" or "the Company") Total Voting Rights Abcam plc (AIM: ABC), the rapidly growing company that markets antibodies via anonline catalogue, announces that in conformity with the Transparency Directive'stransitional provision 6, the Company would like to notify the market of thefollowing: The Company's capital consists of 34,568,264 ordinary shares with voting rights.No ordinary shares are held in treasury. Therefore the total number of Ordinary Shares in the Company with voting rightsis 34,568,264. The above figure of 34,568,264 ordinary shares may be used by shareholders asthe denominator for the calculations by which they will determine if they arerequired to notify their interest in, or a change to their interest in, theCompany under the FSA's Disclosure and Transparency Rules. -End- For further information please contact: Abcam plc + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerEddie Powell, Chief Financial Officerwww.abcam.com Buchanan Communications on behalf of Abcam + 44 (0) 20 7466 5000Mary-Jane Johnson Notes for editors About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcamwas admitted to AIM in November 2005 and trades under the ticker symbol ABC.The Company produces and distributes its own and third party produced antibodiesto academic and commercial users throughout the world with product informationprovided and ordering available through the Company's website, www.Abcam.com.The antibodies are sold almost entirely under the Abcam brand name. TheCompany's vision is to build the largest online antibody resource in the worldwhile also ensuring that the antibodies are of high quality and commerciallyviable. Abcam now has an online catalogue of 25,000 products, most of which areantibodies, from over 200 suppliers supported by up-to-date and detailedtechnical data sheets, which are created by the Company. The Company currentlyemploys 100 staff. About antibodies Antibodies are proteins produced by white blood cells in response to theintroduction of a foreign body known as an antigen. Antibodies, which have awide variety of uses in research, diagnostics and therapeutics, are used bybioscientists in research into disease and into the human genome, where they areused to mark and identify specific cells and other living matter. The number ofhuman antibodies of use in research is potentially greater than one million. This information is provided by RNS The company news service from the London Stock Exchange